MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Regen BioPharma Inc (RGBP)

Regen BioPharma Inc (RGBP)

|||

Cash Flow Overview

Change in Cash
-$32
Unit: Dollar
Positive Cash Flow Breakdown
    • Changes in derivative liability
    • Borrowings from notes payable to...
    • Common stock issued for expenses
    • Others
Negative Cash Flow Breakdown
    • Net income (loss)
    • Repayment of notes payable to re...
    • Increase ( decrease) in unearned...
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
-637,785
991,927
-967,853
-572,469
Changes in derivative liability
623,200
-1,181,680
380,826
299,216
Increase (decrease) in interest expense attributable to amortization of discount
8,754
8,656
8,850
34,234
Common stock issued for compensation
0
0
400,000
-
Common stock issued for expenses
47,897
20,500
-
24,386
(increase) decrease in accounts receivable
27,425
27,424
27,425
27,726
(increase) decrease in prepaid expenses
-
-
-
0
Increase (decrease) in accounts payable
468
9,126
9,310
13
Increase (decrease) in accrued expenses
-7,538
147,302
29,991
63,981
Increase (decrease) in penalties
-
-
-
50,000
Increase ( decrease) in unearned income
-31,640
-31,640
-31,640
-31,640
Net cash provided by (used in) operating activities
-24,069
-63,234
-197,941
-160,005
Increase (decrease)in convertible notes payable
-
0
0
194,599
Increase (decrease) other liabilities
-
-
-
50,000
Increase (decrease)in notes payable
-
58,836
-58,836
-
Repayment of notes payable to related parties
58,836
-
-
-
Common stock issued for cash
0
50,000
191,800
58,200
Borrowings from notes payable to related parties
82,873
-49,910
-
149,631
Net cash provided by (used in) financing activities
24,037
58,926
132,964
227,799
Net increase (decrease) in cash
-32
-4,308
-64,977
67,794
Cash at beginning of period
4,578
4,578
69,555
716
Cash at end of period
239
271
4,578
69,555
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Borrowings from notespayable to related...$82,873 (-63.11%↓ Y/Y)Net cash provided by(used in) financing...$24,037 (-89.30%↓ Y/Y)Canceled cashflow$58,836 Net increase(decrease) in cash-$32 (-103.06%↓ Y/Y)Canceled cashflow$24,037 Changes in derivativeliability$623,200 (65.61%↑ Y/Y)Common stock issued forexpenses$47,897 (-53.82%↓ Y/Y)Increase (decrease) ininterest expense...$8,754 (-51.13%↓ Y/Y)Increase (decrease) inaccounts payable$468 (-42.08%↓ Y/Y)Repayment of notes payableto related parties$58,836 Net cash provided by(used in) operating...-$24,069 (89.24%↑ Y/Y)Canceled cashflow$680,319 Net income (loss)-$637,785 (9.15%↑ Y/Y)Increase ( decrease) inunearned income-$31,640 (66.67%↑ Y/Y)(increase) decrease inaccounts receivable$27,425 (-66.67%↓ Y/Y)Increase (decrease) inaccrued expenses-$7,538 (-106.89%↓ Y/Y)